123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia

Psychopharmacology

Volumn 173, Issue 1-2, 2004, Pages 27-31

  Sjøholm, Hans ^a,b   Bratlid, Trond ^a   Sundsfjord, Johan ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Dopamine; Dopamine transporter; Schizophrenia; SPECT CIT

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; NEUROLEPTIC AGENT; PERPHENAZINE; TROPANE DERIVATIVE; TROPARIL; ZUCLOPENTHIXOL; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; COCAINE; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; SLC6A3 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BASAL GANGLION; BINDING AFFINITY; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYNDROME; HUMAN; IN VIVO STUDY; MALE; MATHEMATICAL COMPUTING; NERVE ENDING; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; BRAIN MAPPING; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; SCINTISCANNING; SYNAPTOSOME;

ADULT; BASAL GANGLIA; BINDING SITES; BRAIN MAPPING; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PRESYNAPTIC TERMINALS; RADIOPHARMACEUTICALS; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 3342935159     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1700-y     Document Type: Article

References (28)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
2. Bannon MJ, Granneman JG, Kapatos G (1995) The dopamine transporter: potential involvement in neuropsychiatric disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York
3. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetaepinephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
4. Carlsson A, Hansson LO, Waters N, Carlsson ML (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75-94
5. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M (1994) Increase in caudate volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151:1430-1436
6. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M (1995) Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345:456-457
7. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC (1999) Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 156:1200-1204
8. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
9. Giros B, Jaber M, Jones SR, Wrightsman RM, Caron MG (1996) Hyperlocomotion and in-difference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612
10. Gur RE, Maany V, Moxley D, Seanson C, Bilker W, Gur RC (1998) Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 155:1711-1717
11. Innis RB, Seibyl JP, Scanly BE, Lamelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Xoghbi S, Wang S, Gao Y, Neumayer JL, Charney DS, Hoffer PB, Marek KL (1993) Single photon computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 90:11965-11969
12. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269-271
13. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115-120
14. 123I) beta-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 13:295-309
15. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, Dsouza CD, Erd J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computed tomography imaging of amphetamine-induced dopamie release in drug-free schizophrenic patients. Proc Natl Acad Sci USA 93:9235-9240
16. 123I) beta-CIT. Biol Psychiatry 47:371-379
17. 11C) N-metylspiperone. Psychiatry Res 61:67-83
18. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 10:81-85
19. Randrup A, Munkvad I (1965) Special antagonism of amphetamine-induced abnormal behaviour. Psychopharmacologica 7:416-422
20. Randrup A, Munkvad I (1967) Stereotyped activity produced by amphetamine in several animal species and man. Psychopharmacologica 11:300-310
21. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar M, Harvey PD, Newman A, Schnur DB, Spiegel-Cohen J, Wei T, Machac J, Lnesaurek K, Vallabhajosula S, Biten MA, Ciaravolu TM, Luu-Hsia C (1998) Dorsal striatal size, shape and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry 55:235-243
22. Sjøholm H, Mellgren SI, Sundsfjord J (1997) Nigro-striatal degeneration demonstrated in parkinsonian patients with iodine-123-beta-CIT SPECT: methods of quantitation. Acta Neurol Scand 96:91-96
23. Tonomi G, Edelmann GM (1998) Consciousness and complexity. Science 282:1846-1851
24. Tuninger E, Levander S (1996) Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 169:618-621
25. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB (2002) Age related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects and hemispheric asymmetries. Am J Geriat Psychiatry 10:36-43
26. van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn 160:492-494
27. van Rossum JM (1967) The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB (eds) 5th Collegium Internationale Neuropsychopharmacologicum. Excerpta Medica, Amsterdam, pp 321-329
28. Wagner HN, Burns DH, Dannals RF, Wong DF, Langstrom B, Duelfer D, Frost JJ, Raert HT, Links JM, Rosenblom SB, Lucas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264-1266